XF-73 green light for the fast track
Destiny Pharma is a UK-based clinical stage developer of medicines for the prevention and treatment of infections caused by drug-resistant bacteria.Destiny has confirmed that its lead candidate, topical antimicrobial XF-73, has been granted FDA Fast Track Designation in the new FDA-backed indication - prevention of post-surgical staphylococcal infection. Following the recent Investigational New Drug (IND) opening, XF-73 is due to enter Phase IIb studies this year, positioning it as a potential first-to-market product in the indication.
Fast track designation is one of a range of incentives granted under Qualified Infectious Disease Product (QIDP) status granted to XF-73. QIDP supports the development of drugs against priority pathogens, such as S aureus, including methicillin-resistant Staphylococcus aureus - MRSA.
XF-73 is the lead product from DEST’s XF series and is a topical gel for nasal administration and the first candidate from the XF group, which collectively have demonstrated activity against a wide spectrum of bacteria tested. These include eight of the twelve pathogens that appear on the priority list classified by the Centers for Disease Control and Prevention (CDC) and the World Health Organisation (WHO).
The value of the primary market for XF-73 alone is an estimated $1.2bn - counting the six million patients classed as high risk who are also carriers of S aureus (based on data from US National Center for Health Statistics). In our view the low potential for resistance means that XF-73 should also be widely adopted for the c12 million high-risk non-carriers of S aureus.
We reiterate our DCF valuation of Destiny Pharma at £115m, or 263p / share, including estimated end December 2017 net cash of £16.8m. On our forecasts the group is well funded to cover the Phase IIb program with XF-73, as well as to cover its initial work on the follow-on pipeline, taking our estimated cash reach to the end of 2020. Our valuation includes only XF-73 in the lead indication, so that the entry of pre-clinical candidates into human studies provides pure upside
Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Motif Bio is a clinical stage biopharmaceutical company based in the United Kingdom. Co. specializes in the development of novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Co.'s predominant product Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia (HABP). Co. is also engaged in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.